

# Rx Inform

Bringing You Key Issues in Prescription Benefits Administration

## IN THIS ISSUE:

## Neupro Recall



### Neupro Being Recalled

The manufacturer of Neupro (rotigotine transdermal system), which is indicated to treat the signs and symptoms of early-stage Parkinson's disease, will recall the medication at the end of April 2008. The product, sold in patches, will not be available in the United States after this date.

Schwarz Pharma, a company of the UCB group, is recalling the product due to a formation of rotigotine crystals in the patches. When the drug crystallizes, less medication is absorbed through the skin, affecting and varying the efficacy of the medication.

Patients currently using Neupro should not stop taking the medication because they must first gradually reduce (down-titrate) their current dosage. Patients should contact their physicians as soon as possible for instructions on how to gradually reduce the amount of Neupro as this may take several days depending on their current doses.

Additional information is available by calling the UCB medical information line toll-free at (800) 477-7877 (choose option 9) or by visiting [www.neupro.com](http://www.neupro.com).

If you have additional questions, please contact your Innoviant account manager at (866) 800-4321.



**Patients currently using Neupro should not stop taking the medication because they must first gradually reduce (down-titrate) their current dosage.**



#### EDITOR:

Julie Bliss,  
Communications Specialist

#### CLINICAL ADVISOR:

Dave Kuzma, R. Ph.  
Clinical Pharmacist

#### INNOVARIANT

11 Scott St., Suite 150  
Wausau, WI 54403-4808  
877-559-2955



**Innoviant**<sup>®</sup>  
Prescription Benefits Administrator